Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Atara Biotherapeutics ( (ATRA) ) has shared an announcement.
On May 12, 2025, Atara Biotherapeutics, Inc. announced a significant workforce reduction, affecting approximately 30% of its employees, with the aim of retaining around 23 essential staff members to focus on strategic priorities. The company anticipates completing this reduction by August 2025, incurring approximately $1.4 million in severance and related benefits, primarily as one-time cash charges, with further details to be disclosed in their upcoming quarterly report.
The most recent analyst rating on (ATRA) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on Atara Biotherapeutics stock, see the ATRA Stock Forecast page.
Spark’s Take on ATRA Stock
According to Spark, TipRanks’ AI Analyst, ATRA is a Underperform.
Atara Biotherapeutics showcases substantial revenue growth, yet its financial instability due to high liabilities and ongoing cash flow challenges significantly impact its attractiveness. The recent positive corporate event regarding the FDA lifting the hold on EBVALLO provides some optimism, but the overall financial risks and negative valuation metrics keep the stock’s score low.
To see Spark’s full report on ATRA stock, click here.
More about Atara Biotherapeutics
Average Trading Volume: 56,540
Technical Sentiment Signal: Sell
Current Market Cap: $43.34M
For detailed information about ATRA stock, go to TipRanks’ Stock Analysis page.